Journal article
Novel Molecules To Treat Chronic Central Nervous System Toxoplasmosis
Journal of medicinal chemistry, v 60(24), pp 9974-9975
28 Dec 2017
PMID: 29200288
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
A major challenge in treating toxoplasmosis in immunocompromised patients is lack of therapeutic agents to clear chronic infection and stop the recrudescence of infection after therapy. CDKP1 has emerged as a novel target for treating chronic infections and eliminating latent bradyzoites in the brain. In a mouse model of toxoplasmosis, pyrazolopyrimidine inhibitors of Toxoplasma gondii CDPK1 demonstrated in vitro and in vivo efficacy.
Metrics
Details
- Title
- Novel Molecules To Treat Chronic Central Nervous System Toxoplasmosis
- Creators
- Sandhya Kortagere - Drexel University
- Publication Details
- Journal of medicinal chemistry, v 60(24), pp 9974-9975
- Publisher
- American Chemical Society; Washington, DC
- Number of pages
- 2
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000419263400004
- Scopus ID
- 2-s2.0-85040002386
- Other Identifier
- 991019167720804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Chemistry, Medicinal